Last reviewed 2026-04-20 · How we verify

Thiomecil (METHYLTHIOURACIL)

Phase 2 active Small molecule

Thiomecil (generic name: METHYLTHIOURACIL) is a methylthiouracil drug. It is currently in Phase 2 development.

Thiomecil works by inhibiting the synthesis of thyroid hormones.

Thiomecil, also known as Methylthiouracil, is a small molecule drug in the methylthiouracil class. Its exact target is unknown, but it is used to treat certain thyroid conditions. The commercial status of Thiomecil is unclear, and it may be available as a generic medication. Key safety considerations include potential liver damage and interactions with other medications. Further research is needed to fully understand its pharmacological properties.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METHYLTHIOURACIL
Drug class	methylthiouracil
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a brake on a car - Thiomecil slows down the production of thyroid hormones, which can help reduce symptoms of overactive thyroid conditions. This is achieved by blocking the enzyme that converts iodine into thyroid hormones, effectively reducing the amount of hormones produced.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Thiomecil CI brief — competitive landscape report
Thiomecil updates RSS · CI watch RSS

Frequently asked questions about Thiomecil

What is Thiomecil?

Thiomecil (METHYLTHIOURACIL) is a methylthiouracil drug.

How does Thiomecil work?

Thiomecil works by inhibiting the synthesis of thyroid hormones.

What is the generic name of Thiomecil?

METHYLTHIOURACIL is the generic (nonproprietary) name of Thiomecil.

What drug class is Thiomecil in?

Thiomecil belongs to the methylthiouracil class. See all methylthiouracil drugs at /class/methylthiouracil.

What development phase is Thiomecil in?

Thiomecil is in Phase 2.

Drug class: All methylthiouracil drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing